Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for Chronic Central Serous Chorioretinopathy
NCT02462499Phase 4Completed
- Sponsor
- Semmelweis University
- Start
- Jun 2014
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eplerenone in Central Serous Chorioretinopathy (CSCR), sponsored by Semmelweis University. Primary endpoints: Resolution of sub-retinal fluid measured by optical coherence tomography (OCT) at 6 months and Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 3 months. Started Jun 2014; status: completed.
02
Drugs
eplerenone
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on NCT02462499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462499.